SCHEMBL30135587

SCHEMBL30135587

O=C(O)CNC(=O)c1ccnc2ccccc12

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NSD2 O96028 1/20 0.62
PREP P48147 5/20 0.55
FAP Q12884 11/20 0.54
DPP7 Q9UHL4 2/20 0.54
PITRM1 Q5JRX3 1/20 0.51
DPP8 Q6V1X1 1/20 0.51
DPP9 Q86TI2 1/20 0.51
FTO Q9C0B1 1/20 0.50
KDM5B Q9UGL1 1/20 0.50
KDM2A Q9Y2K7 1/20 0.50
KDM4C Q9H3R0 1/20 0.49
HDAC3 O15379 1/20 0.48
HDAC4 P56524 1/20 0.48
HDAC1 Q13547 1/20 0.48
HDAC7 Q8WUI4 1/20 0.48
HDAC2 Q92769 1/20 0.48
HDAC10 Q969S8 1/20 0.48
HDAC11 Q96DB2 1/20 0.48
HDAC8 Q9BY41 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15129718 1.00 NSD2 (0.62) NSD2PREPFAPDPP7PITRM1
SCHEMBL24928102 0.84 FAP (0.63) NSD2PREPFAPDPP7PITRM1
SCHEMBL12903049 0.83 NSD2 (0.59) NSD2PREPFAPDPP7PITRM1
SCHEMBL13101452 0.83 FAP (0.53) NSD2PREPFAPDPP7PITRM1
SCHEMBL22367618 0.81 EGLN1 (0.45) NSD2PREPDPP9FTOKDM5B
SCHEMBL2402489 0.81 NSD2 (0.65) NSD2FAPKDM5B
SCHEMBL5603305 0.81 NSD2 (0.56) NSD2PREPFAPDPP7HDAC3
SCHEMBL21101481 0.81 NSD2 (0.57) NSD2PREPFAPDPP7PITRM1
SCHEMBL26965980 0.80 PREP (0.57) NSD2PREPDPP9FTO
SCHEMBL31461294 0.80 EGLN1 (0.51) PREPFTO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240335569-A1 FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND USE THEREOF 3 B Pharmaceuticals GmbH (DE) 2024-10-10 US disclosed
EP-4373529-A1 FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND USE THEREOF 3B Pharmaceuticals GmbH (DE) 2024-05-29 EP disclosed
CN-117769443-A Fibroblast activation protein inhibitor and use thereof 3B制药有限公司 2024-03-26 CN disclosed
WO-2023002045-A1 FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND USE THEREOF 3B PHARMACEUTICALS GMBH (DE) 2023-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240335569-A1 FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND USE THEREOF FIBP, FGF2, FGFR2 NSD2 3751/4885PREP 716/4885FAP 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.